S

Syndax Pharmaceuticals
D

SNDX

12.980
USD
0.97
(8.03%)
Market Closed
Volume
48,698
EPS
-3
Div Yield
-
P/E
-3
Market Cap
1,116,596,634
Related Instruments
A
AKTX
-0.13000
(-10.57%)
1.10000 USD
A
ARWR
0.475
(3.89%)
12.680 USD
C
CRSP
1.090
(3.29%)
34.200 USD
E
EDIT
0.05500
(4.85%)
1.19000 USD
I
IONS
1.455
(5.34%)
28.715 USD
N
NTLA
0.65000
(9.77%)
7.30500 USD
S
SGMO
0.08580
(15.15%)
0.65200 USD
V
VKTX
1.780
(7.44%)
25.700 USD
More
News

Title: Syndax Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.